ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.91% | 82.24% | -440.57% | 18.31% | -42.03% |
| Total Depreciation and Amortization | 1.03% | -14.53% | 7.04% | -0.51% | -0.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.52% | -97.18% | 6,438.01% | 38.26% | -5.71% |
| Change in Net Operating Assets | 1,280.78% | 96.58% | -301.23% | -22.85% | 453.12% |
| Cash from Operations | 28.52% | 47.90% | -245.42% | 26.15% | 31.56% |
| Capital Expenditure | -- | -- | 91.36% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 447.15% |
| Cash from Investing | -- | -- | 16,618.52% | -100.70% | 520.92% |
| Total Debt Issued | 9.20% | -65.00% | 1,566.67% | -25.00% | -- |
| Total Debt Repaid | 43.67% | -829.41% | 99.35% | -2,919.77% | 74.78% |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 18.71% | -68.84% | 377.88% | 224.58% | 190.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.29% | -177.66% | 409.38% | -281.02% | 95.78% |